NBS-C BioScience & Consulting

NBS-C BioScience & Consulting

Vienna, Austria· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2008 and based in Vienna, NBS-C BioScience & Consulting operates as a specialized service provider in the biologics and diagnostics sectors. Its core business leverages Surface Plasmon Resonance (SPR) technology to offer critical analytical services for drug development, including mechanistic studies, biosimilar profiling, and immunogenicity assessment. Additionally, the company has a product arm developing and manufacturing monoclonal antibodies, recombinant proteins, and assay components for the allergy diagnostics market, positioning it at the intersection of contract research and reagent supply.

ConsultingBiologics

Technology Platform

Expertise in Surface Plasmon Resonance (SPR) using Biacore™ systems for label-free, real-time analysis of binding kinetics, affinity, and specificity of biomolecular interactions.

Opportunities

Growing demand for biologics characterization and biosimilar development drives need for sophisticated SPR services.
The expanding allergy diagnostics market creates opportunities for high-specificity reagent sales.
Potential to form strategic partnerships with larger CROs or diagnostic firms to scale operations.

Risk Factors

Client concentration risk and reliance on a single core technology platform (SPR).
Competition from larger, full-service CROs and established reagent suppliers.
Limited financial and marketing resources as a small private company.

Competitive Landscape

NBS-C competes with other specialized biophysics CROs and the in-house capabilities of large pharma. In the broader CRO market, it faces competition from giants like Charles River, LabCorp, and IQVIA, though its niche SPR focus is a differentiator. In reagent supply, it competes with large players like Thermo Fisher, Hycor, and ImmunoCAP suppliers.